DYN Stock Overview
A clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Dyne Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$45.39 |
52 Week High | US$46.39 |
52 Week Low | US$6.40 |
Beta | 1.07 |
11 Month Change | 9.43% |
3 Month Change | 63.98% |
1 Year Change | 342.83% |
33 Year Change | 182.10% |
5 Year Change | n/a |
Change since IPO | 89.92% |
Recent News & Updates
Recent updates
Companies Like Dyne Therapeutics (NASDAQ:DYN) Are In A Position To Invest In Growth
Aug 14Dyne Therapeutics: Progress Undenied In DM1 And DMD Trials
May 21We're Not Very Worried About Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate
May 04Dyne: H2 2024 Muscle Disease Data Could Boost Value
Mar 05We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate
Dec 05Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation
Aug 09We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate
Mar 26We Think Dyne Therapeutics (NASDAQ:DYN) Needs To Drive Business Growth Carefully
Dec 10Is Dyne Therapeutics (NASDAQ:DYN) In A Good Position To Invest In Growth?
Aug 26Dyne wins regulatory nod to start trial for myotonic dystrophy candidate
Jul 12Dyne stock rises 12% as FDA lifts hold on starting muscle disorder study of DYNE-251
Jul 05Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation
May 05We're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash Wisely
Jan 12We Think Dyne Therapeutics (NASDAQ:DYN) Can Afford To Drive Business Growth
Sep 29Dyne Therapeutics' chief scientific officer Romesh Subramanian steps down
Jun 02Here's Why We're Not Too Worried About Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation
May 12Dyne Therapeutics EPS beats by $0.10
May 06Could The Dyne Therapeutics, Inc. (NASDAQ:DYN) Ownership Structure Tell Us Something Useful?
Jan 27Dyne Therapeutics posts encouraging data from its pre-clinical myotonic dystrophy trial
Jan 11Beneficiary Dyne Therapeutics rises on competitor Sarepta's miss in DMD trial
Jan 08Shareholder Returns
DYN | US Biotechs | US Market | |
---|---|---|---|
7D | 4.1% | 2.6% | 3.9% |
1Y | 342.8% | 15.3% | 25.3% |
Return vs Industry: DYN exceeded the US Biotechs industry which returned 15.4% over the past year.
Return vs Market: DYN exceeded the US Market which returned 24.9% over the past year.
Price Volatility
DYN volatility | |
---|---|
DYN Average Weekly Movement | 11.0% |
Biotechs Industry Average Movement | 10.5% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 15.1% |
10% least volatile stocks in US Market | 3.2% |
Stable Share Price: DYN's share price has been volatile over the past 3 months.
Volatility Over Time: DYN's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2017 | 152 | John Cox | www.dyne-tx.com |
Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
Dyne Therapeutics, Inc. Fundamentals Summary
DYN fundamental statistics | |
---|---|
Market cap | US$4.59b |
Earnings (TTM) | -US$257.60m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-17.7x
P/E RatioIs DYN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
DYN income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$257.60m |
Earnings | -US$257.60m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -2.57 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did DYN perform over the long term?
See historical performance and comparison